Baillie Gifford & Co. Decreases Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Baillie Gifford & Co. lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 19.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,887,000 shares of the biopharmaceutical company's stock after selling 1,145,656 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 1.0% of Baillie Gifford & Co.'s investment portfolio, making the stock its 24th biggest position. Baillie Gifford & Co. owned about 3.79% of Alnylam Pharmaceuticals worth $1,344,072,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in Alnylam Pharmaceuticals by 47.4% during the first quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company's stock worth $415,000 after acquiring an additional 892 shares in the last quarter. Empowered Funds LLC raised its stake in Alnylam Pharmaceuticals by 3.9% during the first quarter. Empowered Funds LLC now owns 13,849 shares of the biopharmaceutical company's stock worth $2,070,000 after acquiring an additional 524 shares in the last quarter. ProShare Advisors LLC raised its stake in Alnylam Pharmaceuticals by 10.1% during the first quarter. ProShare Advisors LLC now owns 8,827 shares of the biopharmaceutical company's stock worth $1,319,000 after acquiring an additional 809 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System raised its stake in Alnylam Pharmaceuticals by 0.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 137,022 shares of the biopharmaceutical company's stock worth $20,478,000 after acquiring an additional 1,135 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded down $11.48 during trading hours on Tuesday, reaching $268.34. 433,350 shares of the company's stock traded hands, compared to its average volume of 870,447. The stock has a market cap of $34.61 billion, a PE ratio of -106.80 and a beta of 0.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm's 50 day simple moving average is $274.52 and its 200-day simple moving average is $232.41. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. The company's quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 earnings per share. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at $20,563,480. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on ALNY shares. Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Royal Bank of Canada reiterated an "outperform" rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. Needham & Company LLC restated a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, TD Cowen increased their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $294.50.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.